Treatment of non-small-cell lung cancer after progression on nivolumab or pembrolizumab.
Conclusions: In this cohort, only 35.1% of patients eligible for post-PD1 Ab therapy received st. Post-progression survival was not significantly affected by receipt of post-progression therapy. Prospective trials are needed to clarify the benefit of post-PD1 Ab treatments.
PMID: 32489249 [PubMed - in process]
Source: Current Oncology - Category: Cancer & Oncology Tags: Curr Oncol Source Type: research
More News: Cancer | Cancer & Oncology | Docetaxel | Lung Cancer | Non-Small Cell Lung Cancer | Statistics | Tarceva | Taxotere | UK Health